About Us
About Theraly Fibrosis
Theraly is a preclinical-stage company whose mission is to develop innovative treatments for various forms of life-threatening fibrotic disease.
Theraly was founded in 2015 to translate lab discoveries for fibrosis therapy led by Seulki Lee, PhD, Associate Professor of Radiology at the Johns Hopkins School of Medicine. Theraly’s founding programs are based on the discoveries of Dr. Lee’s research team, whose pioneering research elucidated a TRAIL biology pathway underlying the origins of disease in tissue remodeling and fibrosis. The company is focused on developing a potentially universal anti-fibrotic drug.
The lead asset TLY012, a human protein-based DR5 agonist, selectively targets myofibroblasts, one of the significant originators of fibrosis, and reverses established fibrosis in preclinical models of fibrosis in liver, pancreas, and skin. TLY012 has the potential to cure fibrotic diseases, including systemic sclerosis, liver fibrosis/cirrhosis, and chronic pancreatitis, as well as fibrosis driven cancers. TLY012 received US orphan drug status for systemic sclerosis and chronic pancreatitis and is currently entering a Phase 1 clinical trial.
Mission
To develop innovative treatments to help people live better, fuller, and longer lives.
Vision
Respected leader in the discovery and
development of breakthrough medicines.
Core Values
Principles and standards
that are most important to our company.